论文部分内容阅读
目的:观察沙美特罗替卡松联合噻托溴铵治疗COPD的临床疗效。方法:选择51例患者,随机分为2组,对照组23例给予抗感染、化痰、平喘(静滴氨茶碱或多索茶碱)治疗,观察组28例在上述治疗的基础上给予沙美特罗替卡松(250μg/50μg)早晚各1次吸入,联合噻托溴铵胶囊(18μg)每天上午1粒吸入,共观察一个月。在治疗前、治疗一个月后行肺功能检测。结果:在治疗一个月后观察组FEV1优于对照组(P<0.01)。结论:沙美特罗替卡松联合噻托溴铵治疗COPD对患者肺功能和生活质量有明显改善作用,改善COPD的运动耐量,延缓肺功能的下降。
Objective: To observe the clinical efficacy of salmeterol and titalopyribin in combination with tiotropium in the treatment of COPD. Methods: Fifty-one patients were randomly divided into two groups. The control group received anti-infective, phlegm and antiasthmatic (intravenous aminophylline or doxofylline) treatment. On the basis of the above treatment, 28 patients in the observation group Patients were given inhaled salmeterol / fluticasone (250 μg / 50 μg) morning and evening, and tiotropium capsules (18 μg) were inhaled one morning each morning for a total of one month. Before treatment, pulmonary function tests were performed one month after treatment. Results: After one month of treatment, FEV1 in observation group was better than that in control group (P <0.01). Conclusion: The combination of salmeterol and titalopyribin in combination with tiotropium significantly improved the pulmonary function and quality of life in patients with COPD, improved the exercise tolerance of COPD and delayed the decline of pulmonary function.